Insulin degludec is an ultralong-acting basal insulin analogue being developed by Novo Nordisk under the brand name Tresiba. It is administered via subcutaneous injection. It can be given daily or up to three-times a week to help control the blood sugar level of those with diabetes.
ATC prefix
A10
ATC suffix
AE06
IUPAC name
B29N(epsilon)-omega-carboxypentadecanoyl-gamma-L-glutamyl desB30 human insulin
This page contains content from the copyrighted Wikipedia article "Insulin degludec"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.